Boxer Capital Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
Other funds holding SYRE
Boxer Capital Management's SYRE Position: Q3 2026 in Review
Boxer Capital Management increased its Spyre Therapeutics (SYRE) stake by 183% in Q3 2026, buying an estimated $17.6M and bringing the position to 283,054 shares worth $25.2M. The position accounts for 2.19% of the portfolio, ranked #13.
Boxer Capital Management first reported a position in SYRE in Q4 2024 and has held it in 3 quarters since. 286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.
- Boxer Capital Management held 283,054 shares of Spyre Therapeutics worth $25.2M as of Q3 2026.
- Boxer Capital Management bought 183,054 Spyre Therapeutics shares in Q3 2026, an estimated $17.6M.
- Spyre Therapeutics made up 2.19% of Boxer Capital Management's portfolio in Q3 2026, its #13 holding.
- Boxer Capital Management first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 3 quarters since.
- 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.
Based on Boxer Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.